Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese.

ABSTRACT:

Background

Whether rosiglitazone may affect the risk of non-melanoma skin cancer (NMSC) has not been investigated.

Methods

The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 886418 patients with type 2 diabetes were followed up for NMSC incidence until the end of 2009. Incidences for ever-users, never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression. Additional models were created as sensitivity analyses.

Results

There were 103097 ever-users and 783321 never-users, respective numbers of incident NMSC 250 (0.24%

SUBMITTER: Tseng CH 

PROVIDER: S-EPMC4325941 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature